Luye Pharma Correlations
| LYPHF Stock | USD 0.34 0.00 0.00% |
The current 90-days correlation between Luye Pharma Group and Biogen Inc is -0.08 (i.e., Good diversification). The correlation of Luye Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Luye Pharma Correlation With Market
Good diversification
The correlation between Luye Pharma Group and DJI is -0.15 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Luye Pharma Group and DJI in the same portfolio, assuming nothing else is changed.
Luye |
The ability to find closely correlated positions to Luye Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Luye Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Luye Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Luye Pharma Group to buy it.
Moving together with Luye Pink Sheet
| 0.71 | GLABF | Gemina Laboratories | PairCorr |
| 0.63 | MNPR | Monopar Therapeutics Trending | PairCorr |
| 0.61 | TGNA | Tegna Inc | PairCorr |
| 0.66 | EXCH | Exchange Bankshares | PairCorr |
| 0.67 | WMT | Walmart | PairCorr |
| 0.79 | IBM | International Business Earnings Call This Week | PairCorr |
| 0.66 | DIS | Walt Disney | PairCorr |
Moving against Luye Pink Sheet
| 0.83 | RHHBF | Roche Holding AG Earnings Call This Week | PairCorr |
| 0.81 | NVSEF | Novartis AG | PairCorr |
| 0.78 | RHHBY | Roche Holding Earnings Call This Week | PairCorr |
| 0.78 | RHHVF | Roche Holding AG Earnings Call This Week | PairCorr |
| 0.78 | NVS | Novartis AG ADR | PairCorr |
| 0.46 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.42 | NSFDF | NXT Energy Solutions | PairCorr |
| 0.4 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.36 | AZNCF | AstraZeneca PLC | PairCorr |
| 0.34 | ZTLLF | Zonetail | PairCorr |
| 0.53 | INTC | Intel Earnings Call Today | PairCorr |
| 0.46 | XOM | Exxon Mobil Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.43 | HPQ | HP Inc | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Luye Pink Sheet performing well and Luye Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Luye Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ALPMY | 1.08 | (0.32) | 0.00 | 1.74 | 0.00 | 1.68 | 10.71 | |||
| SNY | 1.06 | (0.01) | 0.00 | 4.73 | 0.00 | 2.16 | 10.59 | |||
| AMRN | 3.21 | (0.01) | 0.00 | 0.01 | 3.42 | 6.12 | 18.64 | |||
| NVS | 0.80 | (0.24) | 0.00 | (1.23) | 0.00 | 1.36 | 6.03 | |||
| SCLXW | 12.50 | 1.26 | 0.06 | 0.28 | 13.89 | 60.00 | 109.99 | |||
| BIIB | 1.12 | (0.42) | 0.00 | (2.80) | 0.00 | 1.83 | 6.98 | |||
| GILD | 1.00 | 0.11 | 0.06 | 0.51 | 1.33 | 1.94 | 10.79 | |||
| AZN | 1.15 | (0.16) | 0.00 | 0.39 | 0.00 | 1.87 | 8.50 | |||
| JNJ | 0.76 | (0.18) | 0.00 | 2.59 | 0.00 | 1.70 | 4.50 | |||
| BMY | 1.22 | 0.13 | 0.07 | (4.48) | 1.37 | 2.51 | 14.38 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Luye Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Luye Pharma Corporate Executives
Elected by the shareholders, the Luye Pharma's board of directors comprises two types of representatives: Luye Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Luye. The board's role is to monitor Luye Pharma's management team and ensure that shareholders' interests are well served. Luye Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Luye Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.